| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db9bb13ecbcd12f84b1c840dfc624a33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76ba102ea9c02b6633d64bf09c5b89a4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-175
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2022-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b9acb25139c44c10f0a84a752832bfc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fd32224c0c9cf64450bb8b2129fb258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b297484a713c088746ee9c717cd82e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_214087215b5fc670d96ba4ad58c4a828 |
| publicationDate |
2022-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022261393-A1 |
| titleOfInvention |
Surface layer protein a (slpa) as a therapeutic agent for the treatment of inflammatory diseases |
| abstract |
The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to synthesize surface layer protein A (SlpA). Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant bacterium, for example L. lactis cells, or a therapeutically effective amount of the isolated SlpA. The recombinant bacteria cells or SlpA isolated from the recombinant bacteria can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient. |
| priorityDate |
2021-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |